Advertisement

European Child & Adolescent Psychiatry

, Volume 17, Issue 1, pp 44–53 | Cite as

Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia

  • Stefan Gebhardt
  • Fabian Härtling
  • Markus Hanke
  • Frank M. Theisen
  • Richard von Georgi
  • Phillip Grant
  • Markus Mittendorf
  • Matthias Martin
  • Christian Fleischhaker
  • Eberhard Schulz
  • Helmut Remschmidt
ORIGINAL CONTRIBUTION

Abstract

Objective

To examine relations between movement disorders (MD) and psychopathological symptoms in an adolescent population with schizophrenia under treatment with predominantly atypical antipsychotics.

Method

MD symptoms and psychopathology were cross-sectionally assessed in 93 patients (aged 19.6 ± 2.2 years) using Tardive Dyskinesia Rating Scale (TDRS), Abnormal Involuntary Movement Scale (AIMS), Extrapyramidal Symptom Scale (EPS), Barnes Akathisia Scale (BAS), Brief Psychiatric Rating Scale (BPRS) and the Schedule for Assessment of Negative/Positive Symptoms (SANS/SAPS).

Results

All patients with MD symptoms (n = 37; 39.8 %) showed pronounced global psychpathological signs (SANS/SAPS, BPRS: p = 0.026, p = 0.033, p = 0.001) with predominant anergia symptoms (p = 0.005) and inclinations toward higher anxiety- and depression-related symptoms (p = 0.051) as well as increased thought disturbance (p = 0.066). Both negative symptoms and anergia showed trends for positive correlations with tardive dyskinesia (p = 0.068; p = 0.065) as well as significant correlations with parkinsonism symptoms (p = 0.036; p = 0.023). Akathisia symptoms correlated significantly with hostile and suspicious symptoms (p = 0.013). A superfactor-analysis revealed four factors supporting the aforementioned results.

Conclusion

MD symptoms and psychopathology are in some respects related to each other. Motor symptoms representing on the one hand trait characteristics of schizophrenia might additionally be triggered by antipsychotics and finally co-occur with more residual symptoms within a long-term treatment.

Keywords

movement disorders psychopathology adolescents antipsychotics schizophrenia 

Notes

Acknowledgements

This study was supported by Novartis GmbH, Nürnberg, Germany. We are especially grateful to Sabine Finkenstein and Regina Stöhr for their additional assistance. We also wish to thank all patients for participating in this study.

References

  1. 1.
    Addington D, Addington J, Maticka-Tyndale E (1994) Specificity of Calgary Depression Scale for schizophrenics. Schizophr Res 11:239–244PubMedCrossRefGoogle Scholar
  2. 2.
    Andreasen NC (1982) Negative symptoms in schizophrenia. Arch Gen Psychiatry 39:789–794PubMedGoogle Scholar
  3. 3.
    Andreasen NC (1984) The scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa CityGoogle Scholar
  4. 4.
    Andreasen NC (1984) The scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa CityGoogle Scholar
  5. 5.
    Andreasen NC, Flaum M, Anrdt S, Alliger R, Swayze VW (1991) Positive and negative symptoms: assessment and validity. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Berlin, Heidelberg, Springer, pp 28–51Google Scholar
  6. 6.
    Andreasen NC, Flaum M, Swayze VW, Tyrell G, Arndt S (1990) Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 47:615–621PubMedGoogle Scholar
  7. 7.
    Angermeyer MC (1999) Beeinflussung der Lebensqualität unter Neuroleptika. In: Fegert JM, Häßler F, Rothärmel S (eds) Atypische Neuroleptika in der Jugendpsychiatrie. Stuttgart, New York, Schattauer, pp 219–229Google Scholar
  8. 8.
    Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedGoogle Scholar
  9. 9.
    Barnes TRE, Halstead SM (1988) A scale for rating drug-induced akathisia. Schizophr Res 1:249CrossRefGoogle Scholar
  10. 10.
    Barnes TRE, McPhillips MA (1995) How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative syndroms in schizophrenia. Int Clin Psychopharmacol 10(Suppl 3):115–121PubMedCrossRefGoogle Scholar
  11. 11.
    Bartzokis G, Hill MA, Altshuler L (1989) Tardive dyskinesia in schizophrenia patients; correlation with negative symptoms. Psychiatry Res 28:145–151PubMedCrossRefGoogle Scholar
  12. 12.
    Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, Kelly C, King DJ (2000) Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 29:47–56CrossRefGoogle Scholar
  13. 13.
    Berardi D, Giannelli A, Biscione R, Ferrari G (2000) Extrapyramidal symptoms and residual psychopathology with low-dose neuroleptics. Hum Psychopharmacol 15:79–85PubMedCrossRefGoogle Scholar
  14. 14.
    Bleich A, Brown SL, Kahn R, VanPraag HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14:297–315PubMedGoogle Scholar
  15. 15.
    Bleuler E (1975) Lehrbuch der Psychiatrie. 13th edn. Berlin, Heidelberg, New York, SpringerGoogle Scholar
  16. 16.
    Bobes J, Gibert J, Ciudad A, Alvarez E, Canas F, Carrasco JL, Gascon J, Gomez JC, Gutierrez M (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 27:473–481PubMedCrossRefGoogle Scholar
  17. 17.
    Brown KW, White T (1991) Pseudoakathisia and negative symptoms in schizophrenic subjects. Acta Psychiatr Scand 84:107–109PubMedCrossRefGoogle Scholar
  18. 18.
    Brown KW, White T (1991) The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry 30:1182–1190PubMedCrossRefGoogle Scholar
  19. 19.
    Brown KW, White T (1992) The influence of topography on the cognitive and psychological effects of tardive dyskinesia. Am J Psychiatry 149:1385–1389PubMedGoogle Scholar
  20. 20.
    Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S (1989) Tardive Akathisia: an analysis of clinical features and response to open therapeutic trial. Mov Disord 4:157–175PubMedCrossRefGoogle Scholar
  21. 21.
    Caligiuri MP, Lohr JB, Bracha HS, Jeste DV (1991) Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry 29:139–148PubMedCrossRefGoogle Scholar
  22. 22.
    Campbell M, Grega DM, Green WH, Bennett WG (1983) Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6:207–222PubMedCrossRefGoogle Scholar
  23. 23.
    Campbell M, Palij M (1985) Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull 21:1063–1075PubMedGoogle Scholar
  24. 24.
    Campbell M, Young PI, Bateman DN, Smith JM, Thomas SH (1999) The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol 47:13–22PubMedCrossRefGoogle Scholar
  25. 25.
    Carlsson A, Hansson LO, Waters N, Carlsson ML (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75–94PubMedCrossRefGoogle Scholar
  26. 26.
    Casey DE (1988) Affective disorders and tardive dyskinesia. Encephale 14:221–226PubMedGoogle Scholar
  27. 27.
    Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152:1724–1729PubMedGoogle Scholar
  28. 28.
    Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J (2003) A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 25:530–541PubMedCrossRefGoogle Scholar
  29. 29.
    Cheung P, Schweitzer I, Crowley KC, Yastrubetskaya O, Tuckwell V (1996) Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia. Int Clin Psychopharmacol 11:237–240PubMedCrossRefGoogle Scholar
  30. 30.
    Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love RC (2005) Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 28:163–168PubMedCrossRefGoogle Scholar
  31. 31.
    Cortese L, Caligiuri MP, Malla AK, Manchanda R, Takhar J, Haricharan R (2005) Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Schizophr Res 75:65–75PubMedCrossRefGoogle Scholar
  32. 32.
    Davis EJ, Borde M, Sharma LN (1992) Tardive dyskinesia and Type II schizophrenia. Br J Psychiatry 160:253–256PubMedGoogle Scholar
  33. 33.
    de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD (2004) The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci 254:356–361PubMedCrossRefGoogle Scholar
  34. 34.
    Dollfus S, Ribeyre JM, Petit M (2000) Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. Psychopathology 33:125–130PubMedCrossRefGoogle Scholar
  35. 35.
    Dose M (2000) Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes. Pharmacopsychiatry 33(Suppl):3–13PubMedCrossRefGoogle Scholar
  36. 36.
    Duncan GE, Sheitman BB, Lieberman JA (1999) An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29:250–264PubMedCrossRefGoogle Scholar
  37. 37.
    Fenn DS, Moussaoui D, Hoffmann WF, Kadri N, Bentounssi B, Tilane A, Khomeis M, Casey DE (1996) Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl) 123:206–210CrossRefGoogle Scholar
  38. 38.
    Fenton WS, Wyatt RJ, McGlashan TH (1994) Risk factors for spontaneous dyskinesia. Arch Gen Psychiatry 51:643–650PubMedGoogle Scholar
  39. 39.
    Findling RL, Steiner H, Weller EB (2005) Use of antipsychotics in children and adolescents. J Clin Psychiatry 66(Suppl 7):29–40PubMedGoogle Scholar
  40. 40.
    Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Dell’Osso L, Daneluzzo E, Pini S (2005) Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 159:983–990CrossRefGoogle Scholar
  41. 41.
    Gebhardt S, Härtling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K, Grant P, Martin M, Fleischhaker C, Schulz E, Remschmidt H (2006) Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry 15:371–382PubMedCrossRefGoogle Scholar
  42. 42.
    Gerlach J (1995) Schizophrenie. Dopaminrezeptoren und Neuroleptika. Berlin, SpringerGoogle Scholar
  43. 43.
    Gervin M, Brown S, Lane A, Clarka M (1998) Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 155:1202–1206PubMedGoogle Scholar
  44. 44.
    Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC (1996) Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 6:251–257PubMedGoogle Scholar
  45. 45.
    Gualtieri CT, Breuning SE, Schroeder SR, Quade D (1982) Tardive dyskinesia in mentally retarded children, adolescents and young adults. North Carolina and Michigan studies. Psychopharmacol Bull 18:62–65PubMedGoogle Scholar
  46. 46.
    Gualtieri CT, Schroeder SR, Hicks RE Quade D (1986) Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 43:335–340PubMedGoogle Scholar
  47. 47.
    Guy W (1976) ECDEU Assessment manual for psychopharmacology, revised ed. Washington, DC, US Department of Health, Education and WelfareGoogle Scholar
  48. 48.
    Halstead SM, Barnes TRE, Speller JC (1994) Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 164:177–183PubMedGoogle Scholar
  49. 49.
    Held T, Weber T, Krausz H, Ahle G, Hager B, Alfter D, Schulze T, Knapp M, Maier W, Rietschel M (2000) Klinische Charakteristika von Patienten mit tardiven Dyskinesien. Fortschr Neurol Psychiatr 68:321–331PubMedCrossRefGoogle Scholar
  50. 50.
    Herrera JN, Sramek JL, Costa JF, Roy S, Heh CW, Nguyen BN (1988) High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis 176:558–561PubMedCrossRefGoogle Scholar
  51. 51.
    Honer WG, Kopala LC, Rabinowitz J (2005) Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 19:277–285PubMedCrossRefGoogle Scholar
  52. 52.
    Iager AC, Kirch DG, Jeste DV, Wyatt RJ (1986) Defect symptoms and abnormal involuntary movement in schizophrenia. Biol Psychiatry 21:751–755PubMedCrossRefGoogle Scholar
  53. 53.
    Kay SR (1991) Positive and negative syndroms in schizophrenia: assessment and research. Clinical and experimental psychiatry monograph No.5, Albert Einstein College of Medicine of Yeshiva University Montefiore Medical Centre, Bronx, N.Y., USA. New York, Brunner/MazelGoogle Scholar
  54. 54.
    Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117PubMedGoogle Scholar
  55. 55.
    Kilzieh N, Wood AE, Erdmann J, Raskind M, Tapp A (2003) Depression in Kraepelinian schizophrenia. Compr Psychiatry 44:1–6PubMedCrossRefGoogle Scholar
  56. 56.
    Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993) Depression in first-episode schizophrenia. Am J Psychiatry 150:1643–1648PubMedGoogle Scholar
  57. 57.
    Kumra S, Jacobsen LK, Lenane M, Smith A, Lee P, Malanga CJ, Karp BI, Hamburger S, Rapoport JL (1998) Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 37:221–227PubMedCrossRefGoogle Scholar
  58. 58.
    Liddle PF, Barnes TRE, Speller J, Kibel D (1993) Negative symptoms as a risk factor for tardive dyskinesia. Br J Psychiatry 163:776–780PubMedGoogle Scholar
  59. 59.
    Lowrimore P, Mulvihill D, Epstein A, McCormack M, Wang YH (2004) CAG nucleotide repeat profiles in persons with schizophrenia or schizoaffective disorders with and without tardive dyskinesia: pilot study. Am J Med Genet B Neuropsychiatr Genet 128:15–18PubMedCrossRefGoogle Scholar
  60. 60.
    Maas JW, Conteras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub SE (1993) Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacology 8:97–109PubMedGoogle Scholar
  61. 61.
    McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial J Child Adolesc Psychopharmacol 13:75–82PubMedCrossRefGoogle Scholar
  62. 62.
    McCreadie RG, Srinivasan TN, Padmavati R, Thara R (2005) Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatr Res 39:261–266PubMedCrossRefGoogle Scholar
  63. 63.
    McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon MS (1996) Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 168:221–226PubMedGoogle Scholar
  64. 64.
    Meltzer HY, McGurk S (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255 PubMedGoogle Scholar
  65. 65.
    Miller R, Chouinard G (1993) Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34:713–718PubMedCrossRefGoogle Scholar
  66. 66.
    Miller CH, Fleischhacker WW (2000) Neurologische Neuroleptika-Nebenwirkungen. In: Förstl H (ed.) Klinische Neuro-Psychiatrie. Neurologie psychischer Störungen und Psychiatrie neurologischer Erkrankungen. Stuttgart, New York, Thieme, pp 449–478Google Scholar
  67. 67.
    Miller del D, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA (2005) Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophr Res 80:33–43PubMedCrossRefGoogle Scholar
  68. 68.
    Moscarelli HJ, Maffei C, Cesana BM, Boato P, Farma T, Grilli A, Lingiardi V, Cazzullo CL (1987) An international perspective on assessment of negative and positive symptoms in schizophrenia. Am J Psychiatry 144:1595–1598PubMedGoogle Scholar
  69. 69.
    Müller P (1999) Therapie der Schizophrenie: Integrative Behandlung in Klinik, Praxis und Rehabilitation. Stuttgart, New York, ThiemeGoogle Scholar
  70. 70.
    Nair CJ, Josiassen RC, Abraham G, Stanilla JK, Tracy JL, Simpson GM (1999) Does akathisia influence psychopathology in psychotic patients treated with clozapine? Biol Psychiatry 15:1376–1383CrossRefGoogle Scholar
  71. 71.
    Northoff G (2002) Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 109:1453–1467PubMedCrossRefGoogle Scholar
  72. 72.
    Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997) Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 96:206–216PubMedCrossRefGoogle Scholar
  73. 73.
    Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812CrossRefGoogle Scholar
  74. 74.
    Overall JE, Gorham DR (1976) The brief psychiatric rating scale. In: Guy W (ed) ECDEU assessment manual for pschopharmacology. Revised edision, Rockville. Maryland, pp 157–169Google Scholar
  75. 75.
    Peralta V, Cuesta MJ (1999) Negative, parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited. Schizophr Res 40:245–253PubMedCrossRefGoogle Scholar
  76. 76.
    Pietraszek M (2003) Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pol J Pharmacol 55:133–154PubMedGoogle Scholar
  77. 77.
    Pool D, Bloom W, Mielke DH, Roninger JJ Jr., Gallant DM (1976) A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 19:99–104PubMedGoogle Scholar
  78. 78.
    Putzhammer A, Perfahl M, Pfeiff L, Hajak G (2005) Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 38:132–138PubMedCrossRefGoogle Scholar
  79. 79.
    Quintana H, Keshavan M (1995) Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 34:1292–1296PubMedCrossRefGoogle Scholar
  80. 80.
    Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adoescents. Am J Psychiatry 141:440–442PubMedGoogle Scholar
  81. 81.
    Reinbold H (1999) Biochemische Aspekte zur Entwicklung extrapyramidaler Störungen durch Antipsychotika. In: Bräuning P (ed) Motorische Störungen bei schizophrenen Psychosen. Stuttgart, New York, Schattauer, pp 131–142Google Scholar
  82. 82.
    Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P (2003) Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 108:297–303PubMedCrossRefGoogle Scholar
  83. 83.
    Remschmidt H (2002) Early-onset schizophrenia as a progressive-deteriorating develomental disorder: evidence from child psychiatry. J Neural Transm 109:101–117PubMedCrossRefGoogle Scholar
  84. 84.
    Remschmidt H, Henninghausen K, Clement HW, Heiser P, Schulz E (2000) Atypical neuroleptics in child- and adolescent psychiatry. Eur Child Adolesc Psychiatry 9(Suppl 1):9–19CrossRefGoogle Scholar
  85. 85.
    Remschmidt H, Martin M, Schulz E, Gutenbrunner C, Fleischhaker C (1991) The concept of positive and negative schizophrenia in child and adolescent psychiatry. In: Maneros A, Andresen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Berlin, Heidelberg, Springer, pp 219–242Google Scholar
  86. 86.
    Richardson MA, Haugland G, Craig TJ (1991) Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factos in child and adolecent psychiatry patients. Am J Psychiatry 148:1322–1328PubMedGoogle Scholar
  87. 87.
    Sachdev P, Hume F, Toohey P, Doutney C (1996) Negative symptoms, cognitive dysfunction, tardive akathasia and tardive dyskinesia. Acta Psychiatr Scand 93:451–459PubMedCrossRefGoogle Scholar
  88. 88.
    Sandyk R, Kay SR (1990) The relationship of negative schizophrenia to parkinsonism. Int J Dev Neurosci 55:1–59Google Scholar
  89. 89.
    Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212:11–19CrossRefGoogle Scholar
  90. 90.
    Simpson GM, Lee JH, Zoubok B, Gardos G (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64:171–179PubMedCrossRefGoogle Scholar
  91. 91.
    Strous RD, Alvir JM, Robinson D, Gal G, Sheitman B, Chakos M, Lieberman JA (2004) Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull 30:265–278PubMedGoogle Scholar
  92. 92.
    Tan YL, Zhou DF, Zhang XY (2005) Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 74:263–270PubMedCrossRefGoogle Scholar
  93. 93.
    Turner T (1989) Rich and mad in Victorian England. Psychol Med 19:29–44PubMedCrossRefGoogle Scholar
  94. 94.
    Waddington JL (1995) Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Adv Neurol 65:211–229PubMedGoogle Scholar
  95. 95.
    Waddington JL (1989) Schizophrenia, affective psychoses and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, ist neurobiological determinants and the conflict of paradigms. Int Rev Neurobiol 31:297–353PubMedGoogle Scholar
  96. 96.
    Waddington JL, Youssef HA (1986) Late onset involuntary movements in chronic schizophrenia: relationship of “tardive” dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry 129:616–620CrossRefGoogle Scholar
  97. 97.
    Waddington JL, Youssef HA, Dolphin C, Kinsella A (1987) Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criteria of their abnormality. Arch Gen Psychiatry 44:901–912Google Scholar
  98. 98.
    Waddington JL, Youssef HA, Molloy AG, O’Boyle KM, Pugh MT (1985) Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies. J Clin Psychiatry 46:29–33PubMedGoogle Scholar
  99. 99.
    Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A (2004) Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71:371–375PubMedCrossRefGoogle Scholar
  100. 100.
    Yuen O, Caligiuri MP, Williams R, Dickson RA (1996) Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 168:702–708PubMedCrossRefGoogle Scholar
  101. 101.
    Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S (2003) Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13:319–327PubMedCrossRefGoogle Scholar
  102. 102.
    Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670–671PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag 2008

Authors and Affiliations

  • Stefan Gebhardt
    • 1
  • Fabian Härtling
    • 2
  • Markus Hanke
    • 3
  • Frank M. Theisen
    • 4
  • Richard von Georgi
    • 5
  • Phillip Grant
    • 6
  • Markus Mittendorf
    • 4
  • Matthias Martin
    • 4
  • Christian Fleischhaker
    • 7
  • Eberhard Schulz
    • 7
  • Helmut Remschmidt
    • 4
  1. 1.Department of Psychiatry and PsychotherapyPhilipps-University of MarburgMarburgGermany
  2. 2.Department of Child and Adolescent PsychiatryJohann-Wolfgang-Goethe-University of FrankfurtFrankfurt am MainGermany
  3. 3.Department of Child and Adolescent PsychiatryUniversity of BerneBernSwitzerland
  4. 4.Department of Child and Adolescent PsychiatryPhilipps-University of MarburgMarburgGermany
  5. 5.Department of Medical Psychology and Medical Sociology, Department of MusicscienceJustus-Liebig-University of GiessenGiessenGermany
  6. 6.Institute of Anatomy and Cytology, Department of Medical Psychology and Medical SociologyJustus-Liebig-University of GiessenGiessenGermany
  7. 7.Department of Child and Adolescent PsychiatryAlbert-Ludwigs-University of FreiburgFreiburgGermany

Personalised recommendations